CANFITE BIOPHARMA
Can-Fite BioPharma (TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases.
CANFITE BIOPHARMA
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
1994-01-01
Address:
Petah Tiqva, HaMerkaz, Israel
Country:
Israel
Website Url:
http://www.canfite.com
Total Employee:
1+
Status:
Active
Contact:
+97239241114
Email Addresses:
[email protected]
Total Funding:
79.01 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Apache Amazon JsDelivr Cloudflare JS
Current Employees Featured
Founder
Stock Details
Investors List
Cybele Holdings
Cybele Holdings investment in Venture Round - CanFite BioPharma
SCP Vitalife Partners
SCP Vitalife Partners investment in Venture Round - CanFite BioPharma
Giza Venture Capital
Giza Venture Capital investment in Venture Round - CanFite BioPharma
Ascend Technology Ventures
Ascend Technology Ventures investment in Venture Round - CanFite BioPharma
Yozma Group
Yozma Group investment in Venture Round - CanFite BioPharma
Official Site Inspections
http://www.canfite.com Semrush global rank: 5.11 M Semrush visits lastest month: 1.59 K
- Host name: 82.163.249.48
- IP address: 82.163.249.48
- Location: Israel
- Latitude: 31.5
- Longitude: 34.75
- Timezone: Asia/Jerusalem
More informations about "CanFite BioPharma"
Can-Fite BioPharma Ltd. (CANF)
Jun 30, 2024 For more information please visit: www.canfite.com. View Board of Directors. Investor Contact Information. Company. Can-Fite BioPharma Ltd. 10 Bareket Street, Kiryat Matalon P.O. Box 7537 Petah-Tikva 49170 Israel …See details»
CanFite BioPharma - Crunchbase Company Profile & Funding
CanFite BioPharma closed its last funding round on Aug 8, 2024 from a Post-IPO Equity round. Who are CanFite BioPharma 's competitors? Alternatives and possible competitors to CanFite …See details»
Can-Fite BioPharma - Board of Directors
He served as the Biotechnology Committee Chairman of the United States-Israel Science & Technology Commission (the "USISTC”). Mr. Bornstein is the founder of ILSI - Israel Life …See details»
Can-Fite BioPharma Ltd. - Drug pipelines, Patents, Clinical trials ...
Contacts Can-Fite BioPharma Motti Farbstein [email protected] +972-3-9241114 Dave GentryRedChip Companies, [email protected] 1-407-644-4256 . Phase 2 ... The …See details»
Can-Fite BioPharma Ltd. (CANF) - Yahoo Finance Canada
See the company profile for Can-Fite BioPharma Ltd. (CANF) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Can-Fite BioPharma - Overview
Can-Fite's platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. The latter is highly expressed in inflammatory, cancer and other …See details»
Earnings Estimate Revisions for CanFite Biopharma - Yahoo Finance
Jan 9, 2025 CanFite Biopharma (CANF) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the …See details»
Can-Fite: Breakthrough Findings Demonstrate …
PETACH TIKVA, Israel, June 24, 2024--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address ...See details»
Recognition of the American Society of Clinical Oncology (ASCO) …
Dec 30, 2024 Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium ; Can-Fite enrolls patients for its pivotal Phase III advanced liver cancer studySee details»
Company Information :: Can-Fite BioPharma Ltd. (CANF)
Company Contact Can-Fite BioPharma Ltd. 10 Bareket Street, Kiryat Matalon P.O. Box 7537 Petah-Tikva 49170 Israel Toll-Free: 800-716-4880See details»
Can-Fite BioPharma Ltd. (Can-Fite BioPharma Ltd.) - 药物管线_专 …
了解Can-Fite BioPharma Ltd. (Can-Fite BioPharma Ltd.)公司的药物管线，治疗领域，技术平台，以及它的27项临床试验, 96篇新闻和25篇文献，疾病领域:肿瘤，免疫系统疾病，内分泌与代 …See details»
Can-Fite BioPharma, Ltd. - BIO CEO & Investor Conference | BIO
Feb 7, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ...See details»
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic ...
Nov 11, 2024 Orphan Drug Designation has been granted lately by US FDA RAMAT GAN, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: …See details»
CanFite Biopharma (CANF) Upgraded to Strong Buy: Here's What …
Jan 9, 2025 CanFite Biopharma (CANF) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the …See details»
Projected Income of $325M to Can-Fite Over the Next 10 Years …
Sep 24, 2024 Along with a virtual VetBiotech organization, Vetbiolix exclusively focuses on clinical developments of prescription medicines, diagnostics, nutraceuticals and care products …See details»
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
RAMAT GAN, Israel, June 05, 2024--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule …See details»
Recognition of the American Society of Clinical Oncology (ASCO) …
Dec 30, 2024 [email protected] +972-3-9241114. FAQ. What are the key benefits of Can-Fite's (CANF) Namodenoson drug for liver cancer? Namodenoson offers dual benefits: anti-cancer …See details»
Community Foundation of Greater Flint | Q&A: Dan Kildee on …
3 days ago Dan Kildee joined the Community Foundation of Greater Flint as its new President and CEO on January 6, 2025. With a proven record in significant leadership roles in …See details»
Can-Fite BioPharma - Overview
Piclidenoson (CF101), Can-Fite's lead candidate, is an oral drug that is currently in a Phase III clinical study for the treatment of psoriasis.All human clinical studies have demonstrated this …See details»
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
Jun 5, 2024 For more information please visit: www.canfite.com. Forward-Looking Statements This press release may contain forward-looking statements, about Can-Fite’s expectations, …See details»